| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_086a68f295e770fe8d06bf290fcc7889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08c0290eca6e42b143513b8c6f57cc0d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768 |
| filingDate |
2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da6f073e6e2809aa00ac50c3627ea9d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74fe542e974d9d2d9a79d37125549ec5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fd5580caf416f0205cebf6a4090109d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c18d6c6280c8eb3b40b2648db20ab1d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71a707dfd56b83e1b6f3e6c7c67a8c60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72777a9e5bb11f13549fbe3dbb97f55b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7978622d7c1fe5b12fd4b999f9971ca9 |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020192684-A1 |
| titleOfInvention |
Therapeutic agent containing isolated recombinant oncolytic adenovirus and immune cells and use therefor |
| abstract |
Provided are a therapeutic agent containing isolated recombinant oncolytic adenovirus and immune cells and a use therefor. The therapeutic agent contains: a first composition containing a first active substance located in a first pharmaceutically acceptable carrier, said first active substance containing an isolated conditionally replicating recombinant oncolytic adenovirus into which a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells has been integrated; and a second composition containing a second active substance located in a second pharmaceutically acceptable carrier, the second active substance containing T cell receptor modified immune cells or chimeric antigen receptor modified immune cells. The present therapeutic agent may be used in treating tumors and/or cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114214457-B |
| priorityDate |
2019-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |